Haemonetics logo

HaemoneticsNYSE: HAE

Profile

Sector:

Healthcare

Country:

United States

IPO:

10 May 1991

Next earnings report:

07 February 2025

Last dividends:

N/A

Next dividends:

N/A
$4.34 B
-11%vs. 3y high
88%vs. sector
-73%vs. 3y high
64%vs. sector
-17%vs. 3y high
82%vs. sector
-21%vs. 3y high
50%vs. sector

Price

pre-market | 12 min ago
$86.49+$1.57(+1.85%)

Dividend

No data over the past 3 years
$345.51 M$353.94 M
$345.51 M$33.83 M

Analysts recommendations

Institutional Ownership

HAE Latest News

Wall Street Analysts Think Haemonetics (HAE) Could Surge 25.58%: Read This Before Placing a Bet
zacks.com11 November 2024 Sentiment: POSITIVE

The mean of analysts' price targets for Haemonetics (HAE) points to a 25.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Haemonetics' Q2 Earnings and Revenues Top, Stock Up, Margins Expand
zacks.com11 November 2024 Sentiment: POSITIVE

HAE delivers impressive growth in the top and bottom lines in the second quarter of fiscal 2025.

Haemonetics 2nd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website
prnewswire.com07 November 2024 Sentiment: POSITIVE

Financial release accessible online BOSTON , Nov. 7, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2025, which ended September 28, 2024, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m.

Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE
prnewswire.com04 November 2024 Sentiment: POSITIVE

Donidalorsen will be a first-in-class RNA-targeted medicine for hereditary angioedema, assuming approval Donidalorsen PDUFA date set for August 21, 2025 Donidalorsen has the potential to be Ionis' second independent commercial launch CARLSBAD, Calif. , Nov. 4, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for donidalorsen, an investigational RNA-targeted medicine for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.

Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?
zacks.com31 October 2024 Sentiment: POSITIVE

Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HAE vs. BSX: Which Stock Is the Better Value Option?
zacks.com30 October 2024 Sentiment: NEUTRAL

Investors interested in Medical - Products stocks are likely familiar with Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?

Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity
seekingalpha.com25 October 2024 Sentiment: POSITIVE

Intellia Therapeutics, Inc. achieved positive phase 1/2 results using NTLA-2002 for HAE patients: 8 out of 11 patients taking higher doses of 50 mg of NTLA-2002 were attack-free during the 16-week primary observation period. Despite the stock price trading lower by 20%, the HAE treatment program continues on using NTLA-2002 in the phase 3 HAELO study. The global hereditary angioedema treatment market size is projected to reach $17.31 billion by the end of 2032.

Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
globenewswire.com24 October 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced positive Phase 2 data from the ongoing Phase 1/2 study of NTLA-2002 in patients with hereditary angioedema (HAE), with results continuing to indicate that NTLA-2002 has the potential to eliminate HAE attacks following a one-time infusion. NTLA-2002 is an investigational in vivo CRISPR-based gene editing therapy in development as a one-time treatment for HAE, a rare genetic condition that leads to potentially life-threatening swelling attacks. Results were published online today in The New England Journal of Medicine and will be presented on Saturday, October 26 at the 2024 American College of Allergy, Asthma & Immunology (ACAAI) Scientific Meeting in Boston, Massachusetts.

HAE or BSX: Which Is the Better Value Stock Right Now?
zacks.com14 October 2024 Sentiment: NEUTRAL

Investors interested in stocks from the Medical - Products sector have probably already heard of Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks is more attractive to value investors?

Robust Plasma Sales, New Innovations Aid Haemonetics Stock
zacks.com08 October 2024 Sentiment: POSITIVE

HAE's hospital portfolio is evolving and helping to create new opportunities for growth and diversification.

What type of business is Haemonetics?

Haemonetics Corporation is a global provider of products and services for blood and plasma transfusion. The company was founded in Braintree, Massachusetts in 1971 by Dr. Jack Latham. Initially, the company focused on manufacturing containers and bags for blood collection. Now, the company's main products include: - Donor products - These include automation tools for blood collection and analysis, devices for detecting bacteria and pathogens in blood, and hematocrit testing. - Products for stopping blood loss in patients - These are surgical devices for blood conservation, blood aspiration systems, and blood warming devices.

What sector is Haemonetics in?

Haemonetics is in the Healthcare sector

What industry is Haemonetics in?

Haemonetics is in the Medical Instruments & Supplies industry

What country is Haemonetics from?

Haemonetics is headquartered in United States

When did Haemonetics go public?

Haemonetics initial public offering (IPO) was on 10 May 1991

What is Haemonetics website?

https://www.haemonetics.com

Is Haemonetics in the S&P 500?

No, Haemonetics is not included in the S&P 500 index

Is Haemonetics in the NASDAQ 100?

No, Haemonetics is not included in the NASDAQ 100 index

Is Haemonetics in the Dow Jones?

No, Haemonetics is not included in the Dow Jones index

When was Haemonetics the previous earnings report?

No data

When does Haemonetics earnings report?

The next expected earnings date for Haemonetics is 07 February 2025